|本期目录/Table of Contents|

[1]林敏华,陈家鑫,汪余嘉,等.闽东地区SLCO1B1基因型分布及其对血脂的影响[J].国际心血管病杂志,2022,04:240-243.
　LIN minhua,CHEN jiaxin,WANG yujia,et al.The distribution of SLCO1B1 genotype and its effect on blood lipid levels in Eastern Fujian[J].International Journal of Cardiovascular Disease,2022,04:240-243.
点击复制

闽东地区SLCO1B1基因型分布及其对血脂的影响(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2022年04期
页码:
240-243
栏目:
临床研究
出版日期:
2022-08-30

文章信息/Info

Title:
The distribution of SLCO1B1 genotype and its effect on blood lipid levels in Eastern Fujian
作者:
林敏华; 陈家鑫; 汪余嘉; 林小惠; 陈芯媛; 陈子春
352100 宁德师范学院附属宁德市医院药学部
Author(s):
LIN minhua;  CHEN jiaxin;  WANG yujia;  LIN xiaohui;  CHEN Xinyuan;  CHEN zichun
Department of Pharmacy, Ningde Municipal Hospital Affiliated to Ningde Normal University, Ningde 352100, China
关键词:
SLCO1B1 ; 血脂; 高密度脂蛋白胆固醇; 他汀类药物
Keywords:
SLCO1B1;  Blood lipid;  HDL-cholesterol;  Statins
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2022.04.012
文献标识码:
-
摘要:
目的：探究闽东地区人群SLCO1B1 基因型的分布，结合血脂情况，研究 SLCO1B1 基因型对血脂水平的影响。 方法：收集2020 年3 月至2021 年2 月于宁德师 范学院附属宁德市医院进行SLCO1B1 基因型检测的2 655 例宁德籍贯患者SLCO1B1 基 因型及服用他汀类等降脂药前的血脂水平，采用统计学方法分析SLCO1B1 与血脂水平的 相关性。 结果：闽东地区人群SLCO1B1*1b（388A＞G）基因型分布为AA 5.80%、AG 34.73%、GG 59.47%，SLCO1B1*5（
Abstract:
Objective: To explore the distribution of SLCO1B1 genotypes and the effect of gene polymorphism on blood lipid levels in eastern Fujian. Methods: SLCO1B1 genotypes were collected from 2 655 cases of Ningde native patients who underwent SLCO1B1 genotype de

参考文献/References

[1] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分 会, 等. 血脂异常基层诊疗指南(2019年)[J]. 中华全科医师 杂志, 2019, 18(5):406-416.
[2] Ren J, Grundy SM, Liu J, et al. Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: the results of a 15-year Chinese Multi- Provincial Cohort Study (CMCS)[J]. Atherosclerosis, 2010, 211(1):327-332.
[3] 李莹，陈志红，周北凡，等．血脂和脂蛋白水平对我国中 年人群缺血性心血管病事件的预测作用[J]．中华心血管病 杂志，2004，32(7):643-647．
[4] 王淼, 赵冬, 王薇, 等. 中国35～64岁人群血清甘油三酯与 心血管病发病危险的关系[J]. 中华心血管病杂志, 2008, 36(10):940-943.
[5] Brown EE, Sturm AC, Cuchel M, et al. Genetic testing in dyslipidemia: a scientific statement from the National Lipid Association[J]. J Clin Lipidol, 2020, 14(4):398-413.
[6] 袁小龙，高春梅，梁大虎，等．常见药物转运体基因多 态性对药动学影响及研究进展[J]．中国医院药学杂志， 2016，36(13):1144-1148＋1150．
[7] De Keyser CE, Peters BJ, Becker ML, et al. The SLCO1B1 c.521T＞C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study[J]. Pharmacogenet Genomics, 2014, 24(1):43-51.
[8] Zubiaur P, Benedicto MD, Villapalos-García G, et al. S L C O 1 B 1 p h e n o t y p e a n d C Y P 3 A 5 p o l y m o r p h i s m significantly affect atorvastatin bioavailability[J]. J Pers Med, 2021, 11(3):204-218.
[9] Turongkaravee S, Jittikoon J, Lukkunaprasit T, et al. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statininduced myopathy[J]. Pharmacogenomics J, 2021, 21(3):296- 307.
[10] Tirona RG, Leake BF, Merino G, et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and African- Americans[J]. J Biol Chem, 2001, 276(38):35669-35675.
[11] Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components[J]. J Clin Med, 2019, 9(1):22-58.
[12] SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy—a genomewide study[J]. N Engl J Med, 2008, 359(8):789-799.
[13] Rajput TA, Naveed AK, Farooqi ZR, et al. Effects of two functionally important SLCO1B1 gene polymorphisms on pharmacokinetics of atorvastatin[J]. Pak J Pharm Sci, 2017, 30(4):1363-1370.
[14] Van DE, Stráneck? V, Hartmannová H, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver[J]. J Clin Invest, 2012, 122(2):519-528.
[15] Zhang W, He YJ, Gan Z, et al. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation[J]. Clin Exp Pharmacol Physiol, 2007, 34(12):1240-1244.
[16] 蒋榆辉，刘玲，奚敏，等．SLCO1B1基因多态性与新 生儿高胆红素血症的相关性[J]．临床儿科杂志，2018， 36(9):649-652．
[17] Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1[J]. Pharmacogenomics, 2008, 9(1):19-33.
[18] 续茜桥，徐晓宇，石秀锦，等．药物转运体基因多态性与 不同他汀类药物调脂效果及不良反应的相关性[J]．中国药 房，2017，28(32):4596-4600．
[19] 王凤玲，孟祥云，陈正徐，等．安徽地区汉族心血管疾病 患者SLCO1B1与ApoE基因多态性分布及其在他汀类药物 临床个体化应用中的意义[J]．中国临床药理学与治疗学， 2021，26(1):40-48．
[20] 王京伟，李艳，乔斌，等．华中地区汉族人群SLCO1B1 与APOE基因多态性分析及临床意义[J]．实用医学杂志， 2018，34(18):3041-3046．
[21] Mo Q, Huang S, Ma J, et al. Association between SLCO1B1 polymorphism distribution frequency and blood lipid level in Chinese adults[J]. Br J Biomed Sci, 2021, 78(1):23-27.
[22] Gotto AM Jr, Brinton EA. Assessing low levels of highdensity lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update[J]. J Am Coll Cardiol, 2004,43(5):717-724.
[23] 高辉，王杨，陈婉婷，等．SLCO1B1和APOE基因多态性 与他汀类药物疗效的相关性[J]．实用医学杂志，2019， 35(14):2300-2303．
[24] 孙谦，周辉，郭丽娜．血脂异常人群ApoE和SLCO1B1基 因多态性及相关性研究[J]．现代检验医学杂志，2017， 32(6):28-31．

备注/Memo

备注/Memo:
基金项目：福建省卫生健康青年科研课题（2020QNA091）
通信作者：陈子春， E-mail: ndczc@ndnu.edu.cn。
更新日期/Last Update: 2022-08-30